Assisted Reproductive Technology Market Size and Forecast 2025–2033

The global assisted reproductive technology (ART) market is entering a period of profound transformation. According to Renub Research, the market—valued at USD 27.76 billion in 2024—is projected to reach USD 49.30 billion by 2033, expanding at a CAGR of 6.59% from 2025 to 2033. This remarkable rise is fueled by increasing infertility rates worldwide, rapid advancements in reproductive medicine, and rising acceptance of fertility treatments across regions. Favorable regulations, improved healthcare access, and technological breakthroughs such as AI-driven embryo selection are collectively reshaping the ART landscape.

Today, ART stands at the intersection of science, society, and shifting family structures—empowering millions to achieve parenthood through medical intervention. As fertility declines globally, these technologies are no longer limited to traditional couples; single individuals, same-sex couples, cancer survivors, and women choosing delayed motherhood are increasingly turning to ART for reproductive support.

This comprehensive analysis explores market drivers, challenges, regional trends, and the evolving competitive landscape, providing an in-depth understanding of the future of assisted reproduction.

Understanding Assisted Reproductive Technology (ART)

Assisted Reproductive Technology refers to medical procedures that involve handling eggs, sperm, or embryos outside the human body to enable conception. These include in vitro fertilization (IVF), artificial insemination (AI), intracytoplasmic sperm injection (ICSI), egg and sperm donation, gestational surrogacy, and cryopreservation of eggs or embryos.

ART has become a lifeline for individuals experiencing infertility due to:

Age-related decline in reproductive health

Hormonal and metabolic disorders such as PCOS

Endometriosis

Male infertility

Genetic conditions

Cancer treatments affecting reproductive organs

Unexplained infertility

Beyond medical needs, ART also supports family building for LGBTQ+ individuals, single parents by choice, and people seeking fertility preservation for lifestyle reasons.

As global demographics shift—marked by longer education cycles, financial pressures, and delayed family planning—the relevance and demand for ART continue to surge.

Key Growth Drivers of the ART Market

1. Rising Global Infertility Rates

Infertility has become a pressing global health concern. The World Health Organization reported in April 2023 that 17.5% of adults worldwide experience infertility—an alarming figure that underscores the need for accessible fertility care. Rates are remarkably similar across income groups, with lifetime infertility reaching 17.8% in high-income countries and 16.5% in low- and middle-income nations.

Several factors contribute to this rise:

Urban lifestyles and work-related stress

Obesity and sedentary habits

Smoking and alcohol consumption

Exposure to endocrine-disrupting chemicals

Late marriages and delayed childbearing

Rise in medical conditions like PCOS and endometriosis

As awareness increases and stigma diminishes, more individuals are actively seeking medical solutions, driving the adoption of IVF, AI, and related procedures.

2. Technological Advancements in Reproductive Medicine

Scientific innovation is revolutionizing ART success rates and accessibility. Key advancements include:

Cryopreservation: Allows long-term storage of eggs, sperm, and embryos without compromising quality.

Preimplantation Genetic Testing (PGT): Ensures healthy embryo selection and reduces genetic disease transmission.

Time-Lapse Imaging: Captures continuous embryo development for precise selection.

AI-enabled embryo selection: Enhances accuracy and increases successful pregnancy outcomes.

Minimally invasive reproductive surgery: Improves recovery times and reduces complications.

Tech-driven companies are also attracting major investments. For instance, in December 2023, Freya BioSciences secured USD 38 million to advance women’s reproductive immunotherapies and expand its biomarker data platform—signaling strong investor interest in next-generation fertility technologies.

3. Supportive Policies and Expanding Insurance Coverage

Governments worldwide are recognizing fertility decline as a national demographic challenge. As a result, many countries are introducing supportive policies that increase ART accessibility.

Key examples include:

Japan’s Children’s Future Strategy (2023): Allocates an additional 3.6 trillion yen annually by 2028 toward fertility initiatives, childcare support, and expanded reimbursement for infertility treatment.

Increasing ART insurance coverage in Europe and select U.S. states.

Growing public campaigns to reduce stigma and encourage early fertility awareness.

Subsidies, reimbursement policies, and standardized regulations enhance affordability, making ART more accessible to middle-income households—historically excluded due to high treatment costs.

Challenges Restraining Market Growth

Despite robust momentum, ART faces significant barriers:

1. High Treatment Costs

ART procedures—particularly IVF—remain prohibitively expensive for many. Costs include:

Hormonal medications

Laboratory testing

Ultrasound monitoring

Embryo transfer

Repeated cycles needed for desired outcomes

Limited insurance coverage in many countries further compounds the affordability challenge.

2. Ethical and Legal Complexities

Regulation and social acceptance vary widely across regions. Key issues include:

Embryo disposal and selection ethics

Donor anonymity debates

Differing surrogacy laws

Cross-border reproductive care

Religious and cultural sensitivities

These inconsistencies restrict market growth and complicate patient access.

ART Market by Procedure Type

In-Vitro Fertilization (IVF)

IVF remains the dominant ART segment, supported by high success rates and advanced technologies such as genetic testing and embryo freezing. IVF uptake continues rising due to:

Age-related fertility decline

Better awareness among couples

Government policies reducing treatment costs

Emerging innovations such as AI-driven embryo grading and non-invasive testing are expected to further strengthen IVF demand.

Artificial Insemination (AI)

Artificial insemination is a less invasive and more affordable option compared to IVF. It is particularly recommended for:

Mild male infertility

Unexplained infertility

Cervical mucus problems

Mild endometriosis

AI’s simplicity, lower cost, and decent success rates make it a popular first-line treatment, contributing meaningfully to overall ART adoption.

ART Market by End Users

Hospitals

Hospitals with dedicated ART units offer advanced diagnostic imaging, laboratory services, and multidisciplinary expertise. Many large hospitals have established fertility wings equipped with cutting-edge technologies, boosting patient confidence and improving treatment outcomes.

Fertility Clinics

Fertility clinics are the backbone of the ART industry. Their services include:

IVF cycle management

Donor programs

Genetic testing

Surrogacy coordination

Counseling and emotional support

The rapid rise of specialized clinics—particularly in India, Europe, and Southeast Asia—is accelerating global market expansion.

Other End Users

These include research institutes, donor banks, and mobile fertility services, which play crucial roles in innovation and accessibility.

Regional Market Overview

United States

The U.S. ART market thrives on advanced healthcare infrastructure, high awareness levels, and cutting-edge technological adoption. Increased insurance coverage in several states and a growing culture of fertility preservation have further strengthened demand. The CDC highlights millions of IVF cycles annually, and government initiatives are actively working to reduce stigma associated with ART.

With rising demand and expanding specialized clinics, the U.S. remains a leading global hub for reproductive medicine.

United Kingdom

The UK’s market benefits significantly from NHS support for fertility treatments. Innovations in IVF, AI, and gamete preservation are making ART more effective and affordable. Awareness campaigns have improved acceptance, and telemedicine is simplifying ART consultations.

In December 2023, TMRW Life Sciences entered the UK fertility market, introducing an automated egg and embryo storage system—its first deployment outside the U.S.

India

India has become a high-growth ART destination due to:

Affordable treatment costs

Highly skilled fertility specialists

Growing fertility tourism

Rising rates of delayed parenthood

The government’s ART Regulations (2023) aim to ensure safety, quality, and transparency in fertility treatments, boosting patient trust. While cultural sensitivities still influence acceptance, increased awareness and new technologies continue to propel growth.

Saudi Arabia

Saudi Arabia's ART market is expanding moderately but steadily. Vision 2030 has sparked major healthcare modernization, opening pathways for advanced fertility services. Awareness campaigns and specialized clinics offering IVF and AI are increasing acceptance in a traditionally conservative society. As reforms progress, the region is poised for accelerated growth.

Market Segmentation Overview

By Type

In-Vitro Fertilization (IVF)

Artificial Insemination

By End User

Hospitals

Fertility Clinics

Other End Users

By Region

North America (United States, Canada)

Europe (France, Germany, Italy, Spain, UK, Belgium, Netherlands, Turkey)

Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand)

Latin America (Brazil, Mexico, Argentina)

Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

Key companies operating in the global ART market include:

Thermo Fisher Scientific Inc.

Sumitomo Mitsui Financial Group, Inc.

CooperSurgical, Inc.

Fujifilm Holdings Corporation

Merck KGaA

Progyny Inc.

Cosmos Biomedical Ltd.

These companies focus on product innovation, partnerships, strategic investments, and improved laboratory technologies to enhance fertility outcomes and expand global reach.

Final Thoughts

The assisted reproductive technology market is poised for a decade of strong growth, shaped by rising infertility, societal acceptance, and technological innovation. As governments expand support programs and clinics adopt advanced reproductive technologies, ART services are becoming more accessible and efficient.

From AI-enhanced embryo selection to genetic testing and improved cryopreservation, the future of ART promises higher success rates, safer procedures, and more affordable care. By 2033, ART will not only help millions achieve parenthood but will also redefine global reproductive healthcare as a cornerstone of the modern family.